+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks



Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks



Hepatology Research 44(2): 179-186



Rapid virological response (RVR), defined as serum hepatitis C virus (HCV) RNA negativity at 4 weeks, is the most useful predictor of sustained virological response (SVR) to standard pegylated interferon (PEG IFN) plus ribavirin therapy for patients infected with genotype 2 HCV. The aim of the present study was to predict SVR using viral response within 2 weeks of therapy initiation. Of 64 HCV genotype 2 patients with a high viral load treated with standard PEG IFN-α-2b plus weight-based ribavirin for 24 weeks, 58 patients whose adherence was more than 67% were analyzed. RNA and core antigen levels were measured at four time points: the day of therapy initiation, the following day, and at 1 and 2 weeks. SVR was achieved in 73% (47/64) of patients. Univariate analysis of SVR contributing factors showed significant differences with age, bodyweight, white blood cell count, platelet count, fibrosis marker levels, baseline core antigen level and viral response. The area under the receiver-operator curve (AUC) of the core antigen level at 1 week (AUC, 0.940) was the highest among the significant SVR predicting factors. Setting 100 fmol/L as the cut-off value for core antigen level at 1 week, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy for predicting SVR were 100%, 86%, 96%, 100% and 97%, respectively, and for predicting RVR were 66%, 93%, 97%, 46% and 72%, respectively. The HCV core antigen level at 1 week after therapy initiation is the most useful predictor for SVR.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055103692

Download citation: RISBibTeXText

PMID: 23531032

DOI: 10.1111/hepr.12101


Related references

Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatology Research 41(12): 1137-1144, 2011

To investigate the utility of a week-4 virological response for SVR prediction in hepatitis C virus (HCV) genotype 3 patients treated with pegylated interferon and ribavirin for 24 weeks. 2007

Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. Gut and Liver 8(4): 421-427, 2014

Meta-Analysis: Sustained Virologic Response (Svr) in Asian Patients With Infection With Hepatitis C Virus Genotype 6 (Hcv-6) Versus Genotype 1 (Hcv-1) Treated With Pegylated Interferon and Ribavirin (Peg Ifn+Rbv) for 48 Weeks. Gastroenterology 146(5): S-921-S-922, 2014

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47(1): 35-42, 2008

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virology Journal 9: 123, 2012

Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. Hepatology International 8(4): 540-549, 2014

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Journal of Hepatology 56(4): 788-794, 2012

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. International Journal of Molecular Medicine 30(5): 1048-1052, 2012

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52(1): 43-48, 2009

Pegylated Interferon and Ribavirin Therapy for 24 Weeks Versus Shorter Duration for Patients with Hepatitis C Virus Genotype 2 and 3 Infection and Rapid Virologic Response: A Meta-Analysis. Gastroenterology 136(5): A-791, 2009

Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders. Internal Medicine 54(3): 273-279, 2015

Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. Journal of Viral Hepatitis 17(5): 345-351, 2010

Su1065 Longer Therapy With 48 Weeks of Pegylated Interferon and Ribavirin (Peg Ifn+Rbv) Is Superior to 24 Weeks in Patients With Treatment-Naive Hepatitis C Virus Genotype 6 (Hcv-6): A Meta-Analysis of 641 Patients. Gastroenterology 146(5): S-979, 2014

Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin. Journal of Gastroenterology and Hepatology 29(1): 201-207, 2014